Skip to main content
SpringerLink
Log in

Infliximab Provides Short-Term Relief in Crohn’s Disease

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Onrust SV, Lamb HM. Infliximab: a review of its use in Crohn’s disease and rheumatoid arthritis. BioDrugs 1998 Nov; 10 (5): 397–422

    Article  PubMed  CAS  Google Scholar 

  2. Canada T. Focus on infliximab: a TNF-alpha inhibitor that reduces intestinal inflammation in Crohn’s disease refractory to conventional therapy. Formulary 1998 Dec; 33: 1171–89

    Google Scholar 

  3. Caspi A. Infliximab: a novel agent for the treatment of active, moderate-to-severe Crohn’s disease. P&T 1998 Oct; 509–14

  4. Hanauer SB, Meyers S. Management of Crohn’s disease in adults. Am J Gastroenterol 1997 Apr; 92: 559–66

    PubMed  CAS  Google Scholar 

  5. Glickman RM. Inflammatory bowel disease: ulcerative colotis and Crohn’s disease. In: Wilson JD, et al., editors. Harrison’s principles of internal medicine, 12th ed. New York: McGraw-Hill, 1991: 1268–81

    Google Scholar 

  6. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med 1997 Oct 9; 337: 1029–35

    Article  PubMed  CAS  Google Scholar 

  7. Rutgeerts P, D’Haens G, van Deventer SJH, et al. Retreatment with anti-TNFα chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn’s disease [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: A 1078

    Google Scholar 

  8. Centocor Inc. Remicade (infliximab) for IV injection prescribing information for USA. 12 Aug 1998 (Data on file)

  9. Present D, Mayer L, van Deventer SJH, et al. Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn’s disease: a multicenter, randomized, double-blind, placebo-controlled study [abstract]. Am J Gastroenterol 1997 Sep; 92: 1746

    Google Scholar 

  10. McCabe RP, Woody J, van Deventer S, et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A962

    Google Scholar 

  11. ‘Dear Doctor’ letter for infliximab in the US. Reactions 1998 Dec 12; 731: 3

    Google Scholar 

  12. McClellan K. Cytokine-target therapies cost effective in Crohn’s disease? Pharmacoecon & Outcomes News 1999 Jan 23; 196: 3–4

    Google Scholar 

  13. Centocor’s infliximab launched in US. Scrip 1998 Oct 14; 2378: 20

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Infliximab Provides Short-Term Relief in Crohn’s Disease. Drugs Ther. Perspect 13, 1–5 (1999). https://doi.org/10.2165/00042310-199913080-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199913080-00001

Keywords

Search

Navigation